secwatch / observer
8-K filed January 6, 2026, 6:59 PM ET CIK 0001845337
M&A confidence high sentiment neutral materiality 0.90

Day One completes acquisition of Mersana for $25/share cash plus CVRs up to $30.25

Day One Biopharmaceuticals, Inc.

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001104659-26-001127
form_type
8-K
ticker
null
cik
0001845337
company_name
Day One Biopharmaceuticals, Inc.
filed_at
2026-01-06T23:59:59+00:00
discovered_at
2026-05-14T18:02:36.513474+00:00
generated_at
2026-05-16T11:33:29.464625+00:00
sec_items
["1.01", "2.01", "7.01", "9.01"]
event_type
m_and_a
sentiment
neutral
materiality_score
0.9
calibrated_materiality_score
0.9
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001104659-26-001127
json_url
https://secwatch.observer/filing/0001104659-26-001127.json
markdown_url
https://secwatch.observer/filing/0001104659-26-001127.md
text_url
https://secwatch.observer/filing/0001104659-26-001127.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1845337/000110465926001127/0001104659-26-001127-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1845337/000110465926001127/tm261757d1_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Source-grounded claims

ae0dfac7e018bf04400b916e549bcc922e514059

Day One Biopharmaceuticals, Inc. completed an acquisition involving Mersana Therapeutics, Inc. for $25.00 per Target Share plus one non-tradable contingent value right (closed 2026-01-06).

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

SEC 8-K Item 2.01/5.01 confidence 0.9 SEC evidence

82a20b74b5cbdefc730e1ca4862fc81c9a08b8d5

Day One Biopharmaceuticals, Inc. entered into CVR Agreement with Rights Agent (effective 2026-01-06).

on January 6, 2026, the Parent and the Rights Agent entered into the CVR Agreement governing the terms of the CVRs issued pursuant to the Offer and the Merger

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

RPAY

REPAY closes $372M acquisition of KUBRA, funded with new $500M term loan

Repay Holdings Corp June 1, 2026, 4:14 PM ET m_and_a Items 1.01, 2.01, 1.02, 9.01, 2.03, 7.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

Comparable filing

KUBRA became an indirect wholly owned subsidiary of the Company. Pursuant to the Purchase Agreement, the aggregate cash purchase price for the Acquisition was approximately $372 million, subject to customary post-closing adjustments. The closing cash consideration was funded with a combination of cash on hand and borrowings under the Credit Agreement described

Filing page SEC filing

RMIX

Suncrete acquires Nelson Bros. Ready Mix for $42.3M cash + stock; earnout up to $18M

Suncrete, Inc. May 7, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 3.02, 7.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

Comparable filing

Mr. Owens, Ms. Owens and JAO, the “Sellers”), and Jacob Owens in his capacity as representative of the Sellers. The aggregate consideration for the Acquisition consisted of (i) 1,296,456 shares of Class A Common Stock, par value $0.0001 per share, of the Company (“Class A Common Stock”) issued to the Sellers (the “Stock Consideration”) and (ii) a $42.3 million net

Filing page SEC filing

VSEC

VSE completes $2.025B acquisition of Precision Aviation Group; 2025 revenue pro forma +50%

VSE CORP May 7, 2026, 7:59 PM ET m_and_a Items 2.01, 1.01, 2.03, 7.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

Comparable filing

On May 5, 2026, pursuant to the Purchase Agreement, VSE acquired all of the capital stock of PAG HoldCo from the Seller for an up-front consideration equal to $2.025 billion

Filing page SEC filing

OCFC

OceanFirst closes acquisition of Flushing Financial; issues shares to Warburg Pincus

OCEANFIRST FINANCIAL CORP June 1, 2026, 5:19 PM ET m_and_a Items 1.01, 3.02, 2.01, 2.03, 3.03, 5.02, 5.03, 7.01, 9.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

Comparable filing

of Flushing (“ Flushing Common Stock ”) issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was converted into the right to receive 0.85 of a share (the “ Exchange Ratio ”) of common stock, par value $0.01 per share, of OceanFirst (“ OceanFirst Common Stock ” and such consideration, the “ Merger Consideration ”).

Filing page SEC filing

Enviri II Corp

New Enviri completes spin-off; starts trading June 2 under NVRI; ~$1.2B revenue, ~$140M EBITDA

Enviri II Corp June 1, 2026, 5:18 PM ET m_and_a Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

Comparable filing

This Current Report on Form 8-K is being filed in connection with the completion of the spin-off of New Enviri contemplated by the Separation Agreement.

Filing page SEC filing

EWCZ

European Wax Center completes take-private by General Atlantic at $5.80/share; stock delisted

European Wax Center, Inc. May 8, 2026, 7:59 PM ET m_and_a Items 1.01, 1.02, 2.01, 2.03, 3.01, 3.03, 5.02, 5.03, 5.01, 8.01, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 9.01 same event type: m_and_a similar materiality

This filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

Comparable filing

excluded shares pursuant to the terms of the Merger Agreement, was cancelled and extinguished and automatically converted into the right to receive an amount in cash equal to $5.80 per share of Class A Common Stock, without interest thereon (the “ Class A Per Share Price ”), (ii) each share of the Company’s Class B common stock, par value $0.00001 per share

Filing page SEC filing

APAD

Enhanced Group completes de-SPAC merger with Enhanced Ltd; redemptions of $201.7M

Enhanced Group Inc. May 8, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 5.06, 3.02, 9.01, 4.01, 3.01, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

Comparable filing

On May 7, 2026, as contemplated by the Business Combination Agreement and as described in the section titled “ The BCA Proposal ” beginning on pa ge 180 of the Proxy Statement/Prospectus, the Company, Enhanced and Merger Sub consummated the business combination contemplated by the Business Combination Agreement, whereby: • Merger Sub merged with and into Enhanced (the “First Merger”), with Enhanced surviving the merger as a wholly owned subsidiary of the Company;

Filing page SEC filing

SHPH

Shuttle Pharma completes merger with United Dogecoin, pivots to crypto, raises $9.55M PIPE

Shuttle Pharmaceuticals Holdings, Inc. May 7, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 3.02, 3.03, 5.02, 5.03, 9.01

same fact type: ma_transaction, material_agreement same SEC item: 1.01, 2.01, 9.01 same event type: m_and_a similar materiality

This filing

offer to purchase all of the issued and outstanding shares (the “ Target Shares ”) of Target’s common stock, par value $0.0001 per share (the “ Target Common Stock ”), for (i) $25.00 per Target Share (the “ Upfront Consideration ”), net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent

Comparable filing

On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).

Filing page SEC filing

Source: SEC EDGAR
accession 0001104659-26-001127

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.